Live Breaking News & Updates on ஆரோக்கியம் கனடா ஒப்புதல்
Stay updated with breaking news from ஆரோக்கியம் கனடா ஒப்புதல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cell MedX Corp. Files Premarket Notification (510K) with the US Food and Drug Administration and Receives Canadian Trademark finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Acerus Reports First Quarter 2021 Financial Results Nachrichtenquelle: globenewswire | 13.05.2021, 13:30 | 54 | 0 TORONTO, May 13, 2021 (GLOBE NEWSWIRE) Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2021. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1 - 2021 Highlights Re-purchased all remaining NATESTO rights from Aytu Biopharma, allowing Acerus to build and leverage its commercial business across North America Expanded NATESTO access to 20 countries across Europe, Central Asia and the Middle East through an agreement with Maylen Farma (“Maylen”), a firm ....
iii MISSISSAUGA, ON, April 15, 2021 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that Health Canada has granted EVRYSDI Ⓡ (risdiplam) market authorization for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older. iii EVRYSDI works by helping the body make more of a protein called, SMN protein. EVRYSDI increases and sustains the amount of SMN protein in the body, which helps to treat SMA. It is the first medicine for SMA that can be taken at home and is administered once daily by mouth or feeding tube. iii The Health Canada approval of EVRYSDI is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases survival motor neuron (SMN) protein in SMA patients, said Dr. Hugh McMillan, Pediatric Neurologist at the Children s Hospital of Eastern Ontario. We now have an additional and convenient treatment option with EVRYSDI, as it s the first at-home and ora ....
Share: TORONTO, March 11, 2021 (GLOBE NEWSWIRE) Acerus Pharmaceuticals Corporation ( Acerus or the Company ) (TSX:ASP, OTCQB:ASPCF) today reported its financial results for the three and twelve-month period ended December 31, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards ( IFRS ). Recent Highlights Significant growth in US NATESTO® total prescriptions during the fourth quarter of 2020 – driven by the specialist (urologist and endocrinologist) segment Rights offering completed in November 2020, strengthening the balance sheet Shipments of NATESTO® to South Korea and Taiwan resumed in the fourth quarter The Company entered into an agreement with Torreya Partners LLC to identify strategic options for product acquisition and growth capital ....
Crescita Announces Filing of New Medical Device License News provided by Share this article ART-FILLER ® Injectables in Canada LAVAL, QC, Jan. 21, 2021 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) and (OTC US: CRRTF) ( Crescita or the Company ), a commercial dermatology, today announced that Laboratoires FILLMED ( FILLMED ) has submitted a New Medical Device License ( MDL ) application for the ART FILLER ® range of products. Crescita and FILLMED entered into an agreement in January 2020, granting Crescita the exclusive rights to distribute the ART-FILLER injectables product range and the New Cellular Treatment Factor ® ( NCTF ® ) in Canada. The ART FILLER is an exclusive collection of five hyaluronic acid ( HA )-based fillers. Since it was developed in 2016, healthcare professionals including dermatologists and plastic surgeons outside Canada have used it to create or restore the volumes and contours of the face, to temporarily ....